Cancer Journey


VIDEOS

2020 TTF EGFR QA PANEL Updates on the Combination Treatment of Osimertinib (Tagrisso) and Ramucirumab (Cyramza)

We continue to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year's live-online...

2020 CBPD LEVY - Stage IV NSCLC ALK Positive 74 YO Male with Brain Metastasis

For this series of case based panel discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for...

2020 CBPD - LEVY - NSCLC KRAS 71 YO Female with Underlying Autoimmune Condition

For this series of case based panel discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for...

2020 CBPD LEVY - CASE 1 - Timing and Treatment for 48 YO Male with EGFR NSCLC High PDL1

For this series of Case Based Panel Discussions, Dr. Benjamin Levy is joined by Dr. Stephen Liu and Dr. Julie Brahmer to discuss treatment for...

2020 TTF EGFR SESSION - QA PANEL Preferred Chemo Regimen when Targeted Therapy Options are Exhausted

We are excited to be able to present final videos from this highly anticipated annual event, the 2020 Targeted Therapies Patient Forum. This year's...

ARTICLES

New FDA Approval for Zykadia (ceritinib) for ALK-Positive NSCLC: Why I Think It's a Poor Choice for Initial Treatment

The FDA just approved a new therapy for the approximately 4% of patients with NSCLC who have the molecular marker known as an ALK rearrangement. The...

Targeted Therapies Patient Forum September 2017 Speaker Highlight - James Stevenson, MD

GRACE is excited to continue to build the faculty and agenda for the upcoming Targeted Therapies Patient Forum, September 16, 2017. See more information about our presenters in Speaker Highlights - today we introduce James Stevenson, MD.

Translation of Molecular Genetics in Lung Cancer into Treatment Decision

Christine M. Walko, Pharm.D., discusses how advancements in technology have improved the quality, cost and turnaround time for assessing genetic mutations in tumor tissue, and how this has helped to translate precision medicine into standard clinical practice.

Imprecision Medicine: Why Keytruda (Pembrolizumab) + Chemo for PD-L1+ NSCLC isn't Ready for Prime Time

Let me start by saying that I'm a fan of the immune checkpoint inhibitor Keytruda (pembrolizumab) and consider it the new standard of care as a single...

First Line Immunotherapy for Advanced Non-Small Cell Lung Cancer: A Great Option for Some, but Not for All

Several weeks ago, at a very crowded plenary session for the European Society of Medical Oncology (ESMO) in Copenhagen, Denmark, results with first...

ONLINE COMMUNITY

RECENT POSTS

Dr. Ravi Salgia: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

Article

Dr. Ravi Salgia, from the University of Chicago, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Dr. Sarah Goldberg: Will Our Gains in Targeted Therapies Be Generalizable to a Wider Range of Lung Cancers?

Article

Dr. Sarah Goldberg gives her view on more widespread availability of new mutation tests, provides her perspective on the likelihood that molecular oncology principles and targeted therapies will become more broadly applicable for other LC subtypes.

[powerpress]

Dr. Rosalyn Juergens: How Do You Discuss the Pros and Cons of Molecular Testing, with Potential Delays and Need for Rebiopsy?

Article

Dr. Rosalyn Juergens, McMaster University, reviews how she discusses the potential advantages and disadvantages waiting on molecular marker results and sometimes seeking additional tissue in patients with advanced NSCLC.

[powerpress]

Dr. Phil Bonomi: For Which Advanced NSCLC Patients Do I Recommend Repeat Biopsies If They Have Insufficient Tissue for Molecular Testing?

Article

Dr. Phil Bonomi, from Rush University, describes which patients with advanced non-small cell lung cancer he would recommend getting a repeat biopsy to obtain sufficient tissue to perform molecular marker testing.

[powerpress]

Subscribe to Procedures & Treatments